{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:31:17Z","timestamp":1778668277741,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s10549-008-0306-9","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T01:18:56Z","timestamp":1232414336000},"page":"591-598","source":"Crossref","is-referenced-by-count":28,"title":["Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2\/neu positive metastatic breast cancer: a multicenter phase II trial"],"prefix":"10.1007","volume":"117","author":[{"given":"Elmar","family":"Stickeler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Klar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Watermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Geibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"F\u00f6ldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Gitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"issue":"4905","key":"306_CR1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the Her-2\/Neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712. doi: 10.1126\/science.2470152","journal-title":"Science"},{"issue":"1","key":"306_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-1119(94)00866-Q","volume":"159","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Chamness GC (1995) The C-Erbb-2 Proto-Oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers\u2014a review. Gene 159(1):19\u201327. doi: 10.1016\/0378-1119(94)00866-Q","journal-title":"Gene"},{"issue":"6 (suppl 18)","key":"306_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90103-4","volume":"28","author":"C Lohrisch","year":"2001","unstructured":"Lohrisch C, Piccart M (2001) An overview of Her2. Semin Oncol 28(6 (suppl 18)):3\u201311. doi: 10.1053\/sonc.2001.29713","journal-title":"Semin Oncol"},{"key":"306_CR4","first-page":"127a","volume":"18","author":"L Norton","year":"1999","unstructured":"Norton L, Slamon D, Leyland-Jones B et al (1999) Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2\u00a0+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:127a","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"6","key":"306_CR5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1524-4741.2003.09602.x","volume":"9","author":"CL Vogel","year":"2003","unstructured":"Vogel CL, Franco SX (2003) Clinical experience with trastuzumab (Herceptin). Breast J 9(6):452\u2013462. doi: 10.1046\/j.1524-4741.2003.09602.x","journal-title":"Breast J"},{"issue":"5","key":"306_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3816\/CBC.2003.n.037","volume":"4","author":"JA O\u2019Shaughnessy","year":"2003","unstructured":"O\u2019Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4(5):318\u2013328. doi: 10.3816\/CBC.2003.n.037","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"306_CR7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/sj.onc.1201222","volume":"15","author":"MD Pegram","year":"1997","unstructured":"Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ (1997) The effect of Her-2\/Neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5):537\u2013547. doi: 10.1038\/sj.onc.1201222","journal-title":"Oncogene"},{"issue":"13","key":"306_CR8","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","volume":"18","author":"M Pegram","year":"1999","unstructured":"Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of Her-2\/Neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13):2241\u20132251. doi: 10.1038\/sj.onc.1202526","journal-title":"Oncogene"},{"issue":"Suppl 3","key":"306_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0093-7754(01)90188-5","volume":"28","author":"D Slamon","year":"2001","unstructured":"Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28(Suppl 3):13\u201319. doi: 10.1053\/sonc.2001.22812","journal-title":"Semin Oncol"},{"issue":"2","key":"306_CR10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12012-007-0013-5","volume":"7","author":"L Gianni","year":"2007","unstructured":"Gianni L, Salvatorelli E, Minotti G (2007) Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7(2):67\u201371. doi: 10.1007\/s12012-007-0013-5","journal-title":"Cardiovasc Toxicol"},{"key":"306_CR11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. doi: 10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"306_CR12","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ (2007) American Society of Clinical Oncology Clinical Evidence on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991\u20134008. doi: 10.1200\/JCO.2007.10.9777","journal-title":"J Clin Oncol"},{"issue":"18","key":"306_CR13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","volume":"24","author":"S Chia","year":"2006","unstructured":"Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L (2006) Pegylated liposomal doxorubicin and trastuzumab in her-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24(18):2773\u20132778. doi: 10.1200\/JCO.2005.03.8331","journal-title":"J Clin Oncol"},{"issue":"9","key":"306_CR14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3816\/CBC.2007.n.028","volume":"7","author":"E Andreopoulou","year":"2007","unstructured":"Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F (2007) Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 7(9):690\u2013696. doi: 10.3816\/CBC.2007.n.028","journal-title":"Clin Breast Cancer"},{"key":"306_CR15","first-page":"55a","volume":"21","author":"M Theodoulou","year":"2002","unstructured":"Theodoulou M, Campos SM, Batist G et al (2002) TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21:55a (Abstr 216)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"306_CR16","unstructured":"Trigo J, Climent MA, Lluch A et al. (2003) Liposomal doxorubicin (Myocet) in combination with Herceptin and paclitaxel is active and well tolerated in patients with HER2-positive locally advanced or metastatic breast cancer (LA\/MBC): a phase II study. Poster presented at the 26th annual san antonio breast cancer symposium, San Antonio, Texas, 3\u20136 December 2003"},{"key":"306_CR17","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525\u20133533. doi: 10.1200\/JCO.2007.11.0106","journal-title":"J Clin Oncol"},{"key":"306_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her2 positive early breast cancer: a metaanalysis of published randomized trials. BMC Cancer 7:153\u2013164. doi: 10.1186\/1471-2407-7-153","journal-title":"BMC Cancer"},{"key":"306_CR19","unstructured":"Gianni L, Semiglazov V, Manikhas GM et al. (2007) Neoadjuvant trastuzumab plus doxorubicin, paclitaxel and CMF in locally advanced breast cancer (NOAH trial): feasibility, safety and antitumor effects. ASCO Breast Meeting (2007) (Abstr 144)"},{"issue":"7","key":"306_CR20","first-page":"953","volume":"5","author":"MF Press","year":"1990","unstructured":"Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the Her-2\/Neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5(7):953\u2013962","journal-title":"Oncogene"},{"key":"306_CR21","first-page":"8597","volume":"34","author":"JJ Doyle","year":"2006","unstructured":"Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2006) Chemotherapy and cardiotoxicity in older breast cancer patients: a population based study. J Clin Oncol 34:8597\u20138605","journal-title":"J Clin Oncol"},{"issue":"4","key":"306_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22(4):263\u2013302. doi: 10.2165\/00002018-200022040-00002","journal-title":"Drug Saf"},{"key":"306_CR23","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippmann SM (2005) Typ II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900\u20132902. doi: 10.1200\/JCO.2005.05.827","journal-title":"J Clin Oncol"},{"issue":"Suppl 13","key":"306_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2004.08.006","volume":"31","author":"MS Ewer","year":"2004","unstructured":"Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31(Suppl 13):161\u2013181. doi: 10.1053\/j.seminoncol.2004.08.006","journal-title":"Semin Oncol"},{"issue":"1","key":"306_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94(1):25\u201336. doi: 10.1002\/cncr.10201","journal-title":"Cancer"},{"issue":"8","key":"306_CR26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500\u00a0mg\/m2. Ann Oncol 11(8):1029\u20131033","journal-title":"Ann Oncol"},{"issue":"10","key":"306_CR27","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","volume":"100","author":"M Theodoulou","year":"2004","unstructured":"Theodoulou M, Hudis C (2004) Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 100(10):2052\u20132063","journal-title":"Cancer"},{"issue":"3","key":"306_CR28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C, CAELYX Breast Cancer Study Group (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440\u2013449. doi: 10.1093\/annonc\/mdh097","journal-title":"Ann Oncol"},{"issue":"2","key":"306_CR29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22(2):322\u2013329. doi: 10.1200\/JCO.2004.01.120","journal-title":"J Clin Oncol"},{"issue":"5","key":"306_CR30","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20(5):1215\u20131221. doi: 10.1200\/JCO.20.5.1215","journal-title":"J Clin Oncol"},{"key":"306_CR31","first-page":"18a","volume":"22","author":"AC Wolff","year":"2003","unstructured":"Wolff AC, Bonetti M, Sparano JA, Wang M, Davidson NE, on behalf of ECOG (2003) Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the eastern cooperative oncology group trial E3198. Proc Am Soc Clin Oncol 22:18a (abstr 70)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"306_CR32","doi-asserted-by":"crossref","unstructured":"Untch M, Tjulandin S, Jonat W, Meerpohl H, Lichinitser M, Manikhas GM, J\u00e4nicke F, Muscholl M, pauschinger M, Thomssen C, Lehle M (2007) \u201cEvaluation of first line trastuzumab in combination with epirubicin\/cyclophosphamidefor patients with Her2-positive metastatic breast cancer\u201d SABCS 2007 (abstract 4058)","DOI":"10.1016\/S1359-6349(07)70870-4"},{"key":"306_CR33","unstructured":"Von Minckwitz G, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M (2007) \u201cGeparQuattro: first interim safety analysis of a phase III trial exploring the efficacy of capecitabine and trastuzumab given concomitantly or in sequence to EC-Doc as neoadjuvant treatment of primary breast cancer\u201d. ASCO 2007 (abstract 222)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0306-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:29:05Z","timestamp":1559219345000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0306-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}